11C-UCB-J

DRUG4 trials

Sponsors

Assistance Publique Hopitaux De Paris, Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience, Yale University

Conditions

Alzeihmer diseaseCocaine Use DisorderHealthy ControlsMajor Depressive DisorderMajor depressive disorder with current severe major depressive episodeParkinson's Disease

Phase 2

Imaging Depression in Parkinson's Disease

RecruitingNCT06402955

Yale UniversityMajor Depressive Disorder, Parkinson's Disease

Start: 2024-09-01End: 2029-12-01Target: 120Updated: 2026-03-10

Impact of microglial activation on synaptic density in Alzheimer’s disease

Not yet recruitingCTIS2024-516566-11-00

Groupe Hospitalier Universitaire Paris Psychiatrie Et NeuroscienceAlzeihmer disease

Target: 90Updated: 2025-10-15

Phase 3

MOODBOOSTER« Early efficacy of ketamine compared to placebo, in add-on therapy of venlafaxine for inpatients with severe unipolar major depressive episodes: a double blind randomized controlled trial »

RecruitingCTIS2023-506597-12-00

Assistance Publique Hopitaux De ParisMajor depressive disorder with current severe major depressive episode

Start: 2024-11-20Target: 60Updated: 2024-06-27

Unknown Phase

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

RecruitingNCT04721418

Yale UniversityCocaine Use Disorder, Healthy Controls

Start: 2021-07-20End: 2026-06-30Target: 80Updated: 2025-09-11